Back to all studies
🧴
Phase 1
Dermatology
in-person

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or At…

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Compensation

Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.

Duration

3 months

Location

Maryland

About this study

Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones. People with HIES often have lupus-like disease or atopic dermatitis (skin rash). Researchers want to know if a drug approved to treat other immune system diseases (baricitinib) can help people with HIES. Objective: To test baricitinib in people with HIES wi…

Who can participate

  • • Adults aged 12–99
  • • All genders welcome
  • • Diagnosed with or experiencing hyper ige syndrome from stat3 mutation
  • • Able to attend in-person clinic visits

What's included

  • • Compensation not listed. Many clinical trials cover travel or time, but payment isn't guaranteed. Ask the study team.
  • • All study-related medical care at no cost
  • • Lab work, screenings, and physician consultations
  • • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.

Source: ClinicalTrials.gov record NCT07262983

Ready to Find a Research Study?

Explore clinical trials and paid research opportunities. Compensation varies by study and is never guaranteed.